Results 61 to 70 of about 147,672 (267)
Molecular Oncology, EarlyView.We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau +11 more
wiley +1 more source
Frontiers in Oncology, 2021 Renal cell carcinoma (RCC) is a malignant tumor that can metastasize easily. Hence, many patients have already developed metastasis when they are diagnosed. It is also one of the most common tumors that metastasize to the head and neck through extranodal
Jun Dai +7 more
doaj +1 more source
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
Possible role of human ribonuclease dicer in the regulation of R loops
FEBS Open Bio, EarlyView.R loops play an important role in regulating key cellular processes such as replication, transcription, centromere stabilization, or control of telomere length. However, the unscheduled accumulation of R loops can cause many diseases, including cancer, and neurodegenerative or inflammatory disorders. Interestingly, accumulating data indicate a possible
Klaudia Wojcik +2 more
wiley +1 more source
Kidney: Papillary renal cell carcinoma [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on Kidney: Papillary renal cell carcinoma, with data on clinics, and the genes involved.
openaire +2 more sources
Understanding miR‐200c: an Important Player in Resistance to Cancer Treatment
Advanced Therapeutics, EarlyView.How can one microRNA alter cancer's response to therapy? miR‐200c plays a central role in therapeutic resistance by modulating epithelial‐mesenchymal transition, apoptosis, cancer stemness features, and drug efflux. This review outlines the context‐dependent functions of miR‐200c in various cancers and highlights its potential as both a biomarker and a
Fatma Sanli, Omer Faruk Karatas
wiley +1 more source
Hereditary papillary renal cell carcinoma [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on Hereditary papillary renal cell carcinoma, with data on clinics, and the genes involved.
openaire +2 more sources
Advanced Science, EarlyView.Cancer cell‐intrinsic SMYD3 orchestrates an immunosuppressive microenvironment and impairs the response to PD‐1 blockade by reprogramming immune cells landscape in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). The immunomodulatory function of SMYD3 is mediated via the SREBP1/CD47 pathway.
Zhengfang Liu +14 more
wiley +1 more source
Advanced Science, EarlyView.This study revealed that oncogene Collaborator of ARF (CARF) is closely related to B‐cell lymphoma tumorigenesis, and shares a conserved mechanism regulating protein stability with Arabidopsis Kip‐Related Protein6 (KRP6) through casein kinase 1‐mediated phosphorylation. Reduced phosphorylation led to the enhanced protein stability of CARF, resulting in
Li Qu +7 more
wiley +1 more source
Hereditary papillary renal cell carcinoma
Seminars in Diagnostic PathologyHereditary papillary renal cell carcinoma (HPRCC) is an autosomal dominant syndrome characterized by the occurrence of bilateral and multifocal, classic type papillary renal cell carcinomas. In the recent decades, extensive molecular studies have narrowed the molecular underpinnings of this syndrome to missense mutations in tyrosine kinase domain of ...
Isa Mulingbayan Jacoba, Zhichun Lu
openaire +2 more sources